JP Morgan Initiates Coverage On Arrowhead Pharma with Overweight Rating, Announces Price Target of $88

Benzinga Newsdesk www.benzinga.com Positive 50.0%

Neg 0% Neu 0% Pos 50%

JP Morgan analyst Brian Cheng initiates coverage on Arrowhead Pharma (NASDAQ:ARWR) with a Overweight rating and announces Price Target of $88.